MX2010003110A - Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas. - Google Patents
Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.Info
- Publication number
- MX2010003110A MX2010003110A MX2010003110A MX2010003110A MX2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A
- Authority
- MX
- Mexico
- Prior art keywords
- line
- methods
- present
- immune response
- polypeptide compositions
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 abstract 3
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
Abstract
La presente invención proporciona polipéptidos de LINE, y composiciones, incluyendo composiciones inmunogénicas, que comprenden un polipéptido de LINE de la invención. La presente invención proporciona un ácido nucleico recombinante que comprende una secuencia de nucleótido que codifica un polipéptido de LINE de la invención Una composición de la invención es útil para estimular una respuesta inmune de célula T para un péptido de LINE. La presente invención además proporciona métodos para estimular una respuesta inmune en un individuo a una célula infectada por retrovirus o lentivirus. La presente invención métodos para tratar cánceres que están asociados con tejidos en los cuales en donde los polipéptidos de LINE son aberrantemente expresados. También se proporcionan métodos para tratar trastornos, que involucran disminuir una respuesta inmune a un polipéptido de LINE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97399307P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/010883 WO2009038756A2 (en) | 2007-09-20 | 2008-09-19 | Long interspersed nuclear element polypeptide compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010003110A true MX2010003110A (es) | 2010-05-19 |
Family
ID=40468692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010003110A MX2010003110A (es) | 2007-09-20 | 2008-09-19 | Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110046042A1 (es) |
| EP (1) | EP2200637A4 (es) |
| JP (1) | JP2010539901A (es) |
| KR (1) | KR20100075483A (es) |
| CN (1) | CN101969987A (es) |
| AU (1) | AU2008301888A1 (es) |
| BR (1) | BRPI0817209A2 (es) |
| CA (1) | CA2700115A1 (es) |
| MX (1) | MX2010003110A (es) |
| RU (1) | RU2010115088A (es) |
| WO (1) | WO2009038756A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2397441T5 (es) | 2006-02-13 | 2022-09-14 | Daiichi Sankyo Co Ltd | Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| US8647640B2 (en) | 2009-06-24 | 2014-02-11 | Richard E. COWART | Vaccine compositions and methods of use to protect against infectious disease |
| CN103517990A (zh) | 2010-10-07 | 2014-01-15 | 通用医疗公司 | 癌症生物标志物 |
| US20150219662A1 (en) * | 2012-06-28 | 2015-08-06 | University Of Louisville Research Foundation, Inc. | Use of protein line-1 orf-1 as a biomarker for cancer |
| EP2875051B1 (en) | 2012-07-19 | 2019-02-20 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibodies |
| JP6830660B2 (ja) * | 2015-04-03 | 2021-02-17 | 国立大学法人京都大学 | がんの治療薬のスクリーニング方法 |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| CA3154827A1 (en) * | 2019-10-16 | 2021-04-22 | Valerio Orlando | Methods for modulating human l1 retrotransposons rna and compositions for use therein |
| WO2021134040A2 (en) * | 2019-12-26 | 2021-07-01 | The Johns Hopkins University | Enhancing expression of line-1 encoded orf2p for cancer therapeutics |
| WO2021246265A1 (ja) * | 2020-06-02 | 2021-12-09 | 学校法人東京女子医科大学 | Ｓ１００ａ８阻害ペプチドとこれを含む疾患治療薬 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280108A (en) * | 1991-09-27 | 1994-01-18 | United States Of America | Antibodies to p40 |
| EP0859625B1 (en) * | 1995-10-20 | 2008-06-25 | University Of Nebraska Board Of Regents | Composition and methods for enhancing immune responses mediated by antigen-presenting cells |
| CN1315379A (zh) * | 2000-03-27 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸 |
| CN1315332A (zh) * | 2000-03-27 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——l1－12和编码这种多肽的多核苷酸 |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| CN1339450A (zh) * | 2000-08-21 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸 |
| CN1339478A (zh) * | 2000-08-21 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸 |
| CN1343776A (zh) * | 2000-09-19 | 2002-04-10 | 上海博德基因开发有限公司 | 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸 |
| CN1352094A (zh) * | 2000-11-06 | 2002-06-05 | 上海博德基因开发有限公司 | 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸 |
| CN1425684A (zh) * | 2001-12-19 | 2003-06-25 | 复旦大学 | 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸 |
| WO2004039952A2 (en) * | 2002-10-25 | 2004-05-13 | Five Prime Therapeutics, Inc. | Methods of use for novel human polypeptides encoded by polynucleotides |
| WO2005012502A2 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| AU2004291828B2 (en) * | 2003-05-28 | 2010-09-23 | The Johns Hopkins University | Synthetic mammalian retrotransposon gene |
-
2008
- 2008-09-19 KR KR1020107007557A patent/KR20100075483A/ko not_active Application Discontinuation
- 2008-09-19 RU RU2010115088/15A patent/RU2010115088A/ru unknown
- 2008-09-19 EP EP08832080A patent/EP2200637A4/en not_active Withdrawn
- 2008-09-19 WO PCT/US2008/010883 patent/WO2009038756A2/en active Application Filing
- 2008-09-19 AU AU2008301888A patent/AU2008301888A1/en not_active Abandoned
- 2008-09-19 US US12/677,278 patent/US20110046042A1/en not_active Abandoned
- 2008-09-19 MX MX2010003110A patent/MX2010003110A/es not_active Application Discontinuation
- 2008-09-19 CN CN2008801164478A patent/CN101969987A/zh active Pending
- 2008-09-19 BR BRPI0817209-9A2A patent/BRPI0817209A2/pt not_active Application Discontinuation
- 2008-09-19 JP JP2010525831A patent/JP2010539901A/ja active Pending
- 2008-09-19 CA CA2700115A patent/CA2700115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010115088A (ru) | 2011-10-27 |
| CA2700115A1 (en) | 2009-03-26 |
| EP2200637A4 (en) | 2011-10-19 |
| WO2009038756A2 (en) | 2009-03-26 |
| EP2200637A2 (en) | 2010-06-30 |
| WO2009038756A3 (en) | 2009-05-14 |
| JP2010539901A (ja) | 2010-12-24 |
| AU2008301888A1 (en) | 2009-03-26 |
| BRPI0817209A2 (pt) | 2015-03-10 |
| KR20100075483A (ko) | 2010-07-02 |
| US20110046042A1 (en) | 2011-02-24 |
| CN101969987A (zh) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010003110A (es) | Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas. | |
| MX2009000659A (es) | Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. | |
| MX2011013183A (es) | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. | |
| EP2470670A4 (en) | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF | |
| MX357562B (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas vip3a de bacillus thuringiensis y metodos para su uso. | |
| TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
| TN2011000283A1 (en) | Human cgrp receptor binding proteins | |
| TN2012000393A1 (en) | Agonist dr5 binding polypeptides | |
| MX2012000202A (es) | Gen plaguicida axmi-205 y metodos para su uso. | |
| MX2011008955A (es) | Proteinas pesticidas y metodos de uso de las mismas. | |
| MX2010008874A (es) | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. | |
| MX363910B (es) | Gen de la toxina axmi270 y sus metodos de uso. | |
| MX2014001070A (es) | Gen plaguicida axmi279 y sus metodos de uso. | |
| MX351526B (es) | Proteinas variantes axmi205 y sus metodos de uso. | |
| MX362999B (es) | Gen de la delta-endotoxina axmi345 y sus metodos de uso. | |
| MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
| MX2019010451A (es) | Genes de las toxinas axmi477, axmi482, axmi486 y axmi525 y sus metodos de empleo. | |
| NZ706884A (en) | Fc gamma receptor iib variants | |
| MX362455B (es) | Gen de la toxina axmi335 de bacillus thuringiensis y sus metodos de uso. | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| WO2015038262A3 (en) | Axmi281 toxin gene and methods for its use | |
| SG10201408245WA (en) | Tmem22 peptides and vaccines including the same | |
| GB201018125D0 (en) | Peptide | |
| UA117731C2 (uk) | Токсин axmi277 проти нематод та його застосування |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |